Evidence map›Paper›PMID 32968142›Full record

ArticleScientific reports2020

Difference in persistent tuberculosis bacteria between in vitro and sputum from patients: implications for translational predictions.

Alan Faraj, Oskar Clewe, Robin J Svensson, Galina V Mukamolova, Michael R Barer, Ulrika S H Simonsson

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 58% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Clinically encountered growth phenotypes of tuberculosis-causing bacilli and theirFrontiers in cellular and infection microbiology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Alan FarajDepartment of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
Oskar CleweDepartment of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
Robin J SvenssonDepartment of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
Galina V MukamolovaLeicester Tuberculosis Research Group, Department of Respiratory Sciences, University of Leicester, Leicester, UK.
Michael R BarerLeicester Tuberculosis Research Group, Department of Respiratory Sciences, University of Leicester, Leicester, UK.
Ulrika S H SimonssonDepartment of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden. ulrika.simonsson@farmbio.uu.se.
Uppsala University · SEUniversity of Leicester · GB

Funding

Biotechnology and Biological Sciences Research Council BB/K000330/1
6 · The paper itself

Abstract

This study aimed to investigate the number of persistent bacteria in sputum from tuberculosis patients compared to in vitro and to suggest a model-based approach for accounting for the potential difference. Sputum smear positive patients (n = 25) provided sputum samples prior to onset of chemotherapy. The number of cells detected by conventional agar colony forming unit (CFU) and most probable number (MPN) with Rpf supplementation were quantified. Persistent bacteria was assumed to be the difference between MPN

Indexed as

Antitubercular AgentsDrug Resistance, BacterialHumansModels, BiologicalMycobacterium tuberculosisSputumStem CellsTuberculosis, PulmonaryAntitubercular Agents

Identifiers

PMID32968142
PMCPMC7511403
OpenAlexW3088643951

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.